EXKIVITY
Total Payments
$8.4M
Transactions
2,630
Doctors
994
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $633,225 | 92 | 2 |
| 2023 | $2.5M | 524 | 96 |
| 2022 | $3.1M | 1,203 | 683 |
| 2021 | $2.2M | 811 | 362 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.6M | 1,055 | 90.5% |
| Consulting Fee | $405,903 | 177 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $285,423 | 104 | 3.4% |
| Travel and Lodging | $49,652 | 106 | 0.6% |
| Food and Beverage | $37,124 | 1,181 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $18,000 | 4 | 0.2% |
| Education | $35.16 | 3 | 0.0% |
Payments by Type
Research
$7.6M
1,055 transactions
General
$796,138
1,575 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER | Takeda Pharmaceuticals U.S.A., Inc. | $3.6M | 0 |
| A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS | Takeda Pharmaceuticals U.S.A., Inc. | $2.5M | 1 |
| A PHASE 1 PHARMACOKINETIC STUDY OF ORAL MOBOCERTINIB IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION | Takeda Pharmaceuticals U.S.A., Inc. | $647,312 | 0 |
| Real-world efficacy and safety | Takeda Pharmaceuticals U.S.A., Inc. | $416,069 | 0 |
| PHASE 1 PHARMACOKINETICS AND SAFETY STUDY OF ORAL MOBOCERTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION | Takeda Pharmaceuticals U.S.A., Inc. | $305,555 | 0 |
| Pre-clinical testing of mobocertinib in combination with chemotherapy in EGFR exon 20 mutant NSCLC | Takeda Pharmaceuticals U.S.A., Inc. | $38,000 | 0 |
| A RANDOMIZED OPEN-LABEL PHASE 2 MULTICENTER STUDY TO EVALUATE THE IMPACT OF MANAGEMENT STRATEGIES ON GASTROINTESTINAL-RELATED ADVERSE EVENTS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR EXON 20 INSERTION MUTATIONS RECEIVING TAK-788 | Takeda Pharmaceuticals U.S.A., Inc. | $34,750 | 0 |
| A PHASE 1/2 STUDY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 IN JAPANESE NON-SMALL CELL LUNG CANCER PATIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $25,685 | 0 |
Top Doctors Receiving Payments for EXKIVITY — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Philadelphia, PA | $3,606 | 4 |
| , M.D, MPH | Hematology & Oncology | Duarte, CA | $3,600 | 1 |
| , M.D | Hematology & Oncology | Philadelphia, PA | $3,500 | 3 |
| , MD | Hematology & Oncology | Baltimore, MD | $3,480 | 1 |
| , M.D | Hematology & Oncology | Sacramento, CA | $3,480 | 1 |
| , MD | Medical Oncology | Los Angeles, CA | $3,443 | 1 |
| , M.D | Hematology & Oncology | Berkeley, CA | $3,300 | 1 |
| , M.D | Hematology & Oncology | Seattle, WA | $3,300 | 2 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $3,300 | 1 |
| , MD | Medical Oncology | Honolulu, HI | $3,163 | 2 |
| , M.D | Medical Oncology | Houston, TX | $3,060 | 1 |
| , MD | Hematology & Oncology | Seattle, WA | $3,060 | 1 |
| , MD | Internal Medicine | Philadelphia, PA | $3,000 | 1 |
| , MD | Medical Oncology | New York, NY | $3,000 | 2 |
| , MD | Internal Medicine | Minneapolis, MN | $2,970 | 2 |
| , MD, MBA, FACP | Hematology & Oncology | Salt Lake City, UT | $2,920 | 1 |
| , MD | Internal Medicine | Detroit, MI | $2,850 | 2 |
| , MD | Medical Oncology | Chicago, IL | $2,850 | 2 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $2,825 | 2 |
| , M.D | Medical Oncology | San Antonio, TX | $2,759 | 4 |
| , MD | Hematology & Oncology | Denver, CO | $2,750 | 2 |
| , MD | Internal Medicine | New Hyde Park, NY | $2,555 | 1 |
| , MD | Internal Medicine | Boston, MA | $2,543 | 1 |
| , M.D., PH.D | Internal Medicine | Columbus, OH | $2,543 | 2 |
| , MD | Internal Medicine | New York, NY | $2,543 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.4M
- Total Doctors 994
- Transactions 2,630
About EXKIVITY
EXKIVITY is a drug associated with $8.4M in payments to 994 healthcare providers, recorded across 2,630 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2021 to 2024. In 2024, $633,225 was paid across 92 transactions to 2 doctors.
The most common payment nature for EXKIVITY is "Unspecified" ($7.6M, 90.5% of total).
EXKIVITY is associated with 8 research studies, including "A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32788) IN NON-SMALL CELL LUNG CANCER" ($3.6M).